What is the main purpose of comparing Zevia PBC and Medifast Inc on this page?

The page aims to present Zevia and Medifast side by side, highlighting how their business models, top-line performance, profitability, and market dynamics differ. It helps readers understand what each company does, how they generate revenue, and how their financial results and environments may influence investment considerations—without giving advice.

How is ‘top-line growth’ relevant in this comparison?

Top-line growth refers to increases in revenue. For Zevia, growth of 12.3% in Q3 2025 suggests stronger sales momentum, while Medifast’s earnings history points to profitability trends rather than a single revenue surge. Understanding revenue trends helps gauge demand and scale, independent of profitability per se.

What does high institutional ownership imply for Zevia in this context?

Institutional ownership of 53.21% in Zevia signals substantial participation from large investors, which can affect price stability and market confidence. It suggests that professional stakeholders are analysing Zevia’s performance, though it does not guarantee future returns or align with any particular investment outcome.

How should I interpret Zevia’s loss per share alongside revenue growth?

Zevia reporting a loss per share of $0.04 amid revenue growth indicates a path to profitability is not yet assured, even with top-line momentum. Investors often weigh whether the company can convert sales gains into sustainable profits, considering operating costs and margins.

What is the significance of gross profit margin changes for Zevia?

A margin decline (3.5 percentage points to 45.6%) signals compressed profitability per unit sold. This could be due to higher costs or pricing pressures. In long-term assessments, analysts compare gross margins to peers and assess whether cost controls can restore profitability.

What advantages does Medifast derive from its subscription-based model?

Medifast benefits from recurring revenue through diet plans and product sales, which can provide more predictable cash flows and customer engagement. This can support more stable earnings and potentially higher customer lifetime value compared with non-subscription models.

What external pressures could affect both Zevia and Medifast in their markets?

Both companies operate in consumer-focused sectors where discretionary spending, promotional activity, and competition impact demand. Economic cycles, consumer sentiment, and evolving dietary trends can influence sales, pricing power, and market share for Zevia and Medifast.

How does competition pose a risk for Medifast?

Medifast faces competition from emerging entrants and established health brands, which can erode market share and pressure pricing. A crowded field requires ongoing product innovation, marketing, and distribution strategies to maintain competitive strength.

Why are regulatory considerations mentioned for Zevia and Medifast here?

Regulatory scrutiny can impact product claims, safety standards, and marketing practices. Zevia’s and Medifast’s businesses may be affected by evolving rules around dietary products and disclosures, influencing compliance costs and strategic directions for each company.

What should a reader take away from the valuation signals in this comparison?

Valuation signals include share price relative to 52-week highs and profitability status. Zevia’s price below its 52-week high may reflect valuation concerns or market perceptions, while Medifast’s profit stability offers a different lens. Consider both growth and profitability when forming a view.

How does this page define ‘market context’ for these stocks?

Market context encompasses industry dynamics, consumer trends, regulatory environments, and competitive landscape. For Zevia and Medifast, it means evaluating how soda alternatives and weight-management products fit into broader consumer health and wellness markets.

Educational disclaimer for readers: how should you use this page?

This page presents educational information to aid understanding of Zevia and Medifast’s business models, financials, and market situations. It does not provide financial advice or buy/sell recommendations, and readers should consult a professional for personalised guidance.

Zevia vs Medifast

Zevia sells zero-sugar, stevia-sweetened beverages and bets on the clean-label wellness trend to pry shelf space away from entrenched soda giants while Medifast markets structured weight loss programs and meal replacements through a direct selling coach network that's been shrinking faster than the company expected. Both companies are selling wellness lifestyles to consumers who want a healthier version of themselves but have struggled to scale revenue beyond their core enthusiast base into true mass-market penetration. The Zevia vs Medifast comparison digs into which brand actually has the product-market fit and unit economics to build a lasting consumer franchise rather than just a niche following.

Zevia sells zero-sugar, stevia-sweetened beverages and bets on the clean-label wellness trend to pry shelf space away from entrenched soda giants while Medifast markets structured weight loss programs...

Comparison Snapshot

Key Financial Metrics

ZVIA

Metric

MED

$96.16M

Market Cap

$120.47M

230.63%

Potential Profit

50.00%

Buy

Analyst Rating

Hold

Investment Analysis

Zevia

ZVIA

Pros

Zevia's net sales grew 12.3% in Q3 2025, showing strong top-line growth momentum.
The company exceeded revenue estimates with $40.84 million in Q3 2025, beating analyst expectations.
Institutional ownership is high at 53.21%, indicating strong institutional investor confidence.

Considerations

Gross profit margin declined by 3.5 percentage points to 45.6% in Q3 2025, suggesting pressure on profitability.
Zevia reported a loss per share of $0.04 in Q3 2025, indicating ongoing net unprofitability.
The stock price is currently below its 52-week high, suggesting possible valuation or market confidence concerns.

Medifast

MED

Pros

Medifast has a strong market position in the weight loss and meal replacement industry.
The company has demonstrated consistent profitability and solid margin management in recent years.
Medifast benefits from recurring revenue via its subscription-based diet plans and product sales.

Considerations

Medifast's business is sensitive to consumer discretionary spending, making it vulnerable in economic downturns.
The company faces increasing competition from both emerging entrants and established health brands.
Regulatory scrutiny on dietary supplements and weight loss claims could pose compliance risks.

Related Market Insights

PepsiCo's Celsius Gambit: Why This Partnership Could Reshape the Energy Drink Wars

Explore how PepsiCo's strategic partnership with Celsius is reshaping the energy drink market. Discover investment opportunities in beverage consolidation & supply chain growth.